SEATTLE--(BUSINESS WIRE)--Sep. 7, 2018--
Omeros Corporation (NASDAQ: OMER), today announced that Gregory A.
Demopulos, M.D., chairman and chief executive officer, will present at
the 16th Annual Morgan Stanley Global Healthcare Conference
in New York next week. The presentation, which will be a fireside chat
format, is scheduled for Thursday, September 13, 2018 at 5:15 p.m. EDT.
The presentation will be webcast. The live and archived webcasts can be
accessed on the “Events” page of the company’s website at www.omeros.com.
About Omeros Corporation
Omeros is a commercial-stage biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, complement-mediated diseases and disorders of the central
nervous system. The company’s drug product OMIDRIA® (phenylephrine and
ketorolac intraocular solution) 1% / 0.3% is marketed for use during
cataract surgery or intraocular lens (IOL) replacement to maintain pupil
size by preventing intraoperative miosis (pupil constriction) and to
reduce postoperative ocular pain. In the European Union, the European
Commission has approved OMIDRIA for use in cataract surgery and other
IOL replacement procedures to maintain mydriasis (pupil dilation),
prevent miosis (pupil constriction), and to reduce postoperative eye
pain. Omeros has multiple Phase 3 and Phase 2 clinical-stage development
programs focused on: complement-associated thrombotic microangiopathies;
complement-mediated glomerulonephropathies; cognitive impairment; and
addictive and compulsive disorders. In addition, Omeros has a diverse
group of preclinical programs and a proprietary G protein-coupled
receptor (GPCR) platform through which it controls 54 new GPCR drug
targets and corresponding compounds, a number of which are in
preclinical development. The company also exclusively possesses a novel
antibody-generating platform.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180907005079/en/
Source: Omeros Corporation
Cook Williams Communications, Inc.
Jennifer Cook Williams
Investor
and Media Relations
360-668-3701
[email protected]
